Eylea and Uveitis - a phase IV clinical study of FDA data

Summary:

Uveitis is reported as a side effect among people who take Eylea (aflibercept), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Beovu, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Uveitis when taking Eylea. It is created by eHealthMe based on reports of 27,819 people who have side effects when taking Eylea from the FDA, and is updated regularly.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

What is Uveitis?

Uveitis (inflammation of the uvea) is found to be associated with 855 drugs and 1,499 conditions by eHealthMe. Check the latest studies of Uveitis.

On Nov, 23, 2025

27,819 people reported to have side effects when taking Eylea.
Among them, 502 people (1.8%) have Uveitis.

Among these 502 people:

How long have people been on Eylea when they have Uveitis? *

What is the gender of people who have Uveitis when taking Eylea? *

female: 63.26 %
male: 36.74 %

What is the age of people who have Uveitis when taking Eylea? *

What are other drugs people take besides Eylea? *

What are other side effects people have besides Uveitis? *

Visual Acuity Reduced (reduced clearness of vision): 94 people, 18.73%
Eye Inflammation: 64 people, 12.75%
Vitritis (inflammation of the vitreous humour of the eye): 59 people, 11.75%
Vitreous Floaters (spots before the eyes): 59 people, 11.75%
Blindness Transient (sudden loss of vision): 57 people, 11.35%
Blindness Unilateral: 56 people, 11.16%
Vision Blurred: 56 people, 11.16%
Endophthalmitis (inflammation of the internal coats of the eye): 39 people, 7.77%
Eye Pain: 36 people, 7.17%
Blindness: 36 people, 7.17%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 111 people, 22.11%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 48 people, 9.56%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 40 people, 7.97%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 26 people, 5.18%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 12 people, 2.39%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 11 people, 2.19%
Wet Macular Degeneration: 8 people, 1.59%
High Blood Pressure: 5 people, 1.00%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 5 people, 1.00%
Retinal Neovascularisation (development of tiny, abnormal, leaky blood vessels inside the retina): 4 people, 0.80%

* Approximation only. Some reports may have incomplete information.

Do you take Eylea and have Uveitis?

- Check whether Uveitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eylea:

Eylea (27,868 reports)

Uveitis treatments and more:

Uveitis (29,545 reports)

Common Eylea side effects:

Browse all side effects of Eylea:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common drugs associated with Uveitis:

Browse all the drugs that are associated with Uveitis:

Uveitis (855 drugs)

Common conditions associated with Uveitis:

Ileitis: 2,805 reports
Inflammatory bowel disease - crohn's disease: 2,804 reports
Spondylarthropathy: 2,703 reports
Rheumatoid spondylitis: 2,702 reports
Arthritis - rheumatoid: 1,413 reports
Rheumatoid arthritis: 1,412 reports
Psoriatic arthropathy aggravated: 649 reports
Juvenile idiopathic arthritis: 576 reports
Malignant melanoma: 518 reports
Hbp: 516 reports

Browse all the conditions that are associated with Uveitis:

Uveitis (1,499 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aflibercept (the active ingredients of Eylea) and Eylea (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.